Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Healthcare Biotechnology
Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Microbix Biosystems Inc > How many new products does it take…
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(92)
•••
Comment by Mbxwatcheron Jun 13, 2023 9:26am
141 Views
Post# 35493325

RE:How many new products does it take…

RE:How many new products does it take…I believe the market needs to see more QAPS deals.

I re-read Bruce Krugels last report just the other day.  At this time the consensus seemed to be almost $10 million of VTM sales per year........not zero.

The Kinlytic deal, while very good, and exciting is still a few years off before it is material (IMO)

The Antigen business is increasing but it is the lowest margin of their business units.

Until then I think the share price reacts to profitability and material QAPS deals.


I am not saying these things wont occur, or that the Kinlytic deal is anything but exciting.
I am only saying that in the short to medium term that new QAPS deals and record quarters is all the market is going to react to.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities